The Latest Breaking News from Ulcerative Colitis

Children as Young as Two with Ulcerative Colitis Can Now Get Stelara After an FDA Label Expansion

FDA cleared Stelara for pediatric ulcerative colitis in children 2 and older. Here is what the trial showed and what families should ask.

Medical Daily · Sep 2

Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

The Economic Times · Aug 18

Ulcerative Colitis Outnumbers Crohn's More Than Two to One Among the 4.1 Million American Adults with IBD

New CDC data show 1.6% of U.S. adults have been diagnosed with inflammatory bowel disease, with ulcerative colitis far more common than Crohn's.

Medical Daily · Aug 18

'My body said stop' – 24-year-old pro cyclist forced to retire amid health struggle

Uno-X Mobility's Anne Dorthe Ysland has been battling ulcerative colitis since 2022

Cycling Weekly · May 5

Ulcerative Colitis Treatment Guide: 5-ASA Therapy, Biologics & Long-Term Remission

Ulcerative colitis control guide covering 5-ASA therapy, biologics, flare treatment, and mucosal healing for long-term remission and reduced colon inflammation.

Medical Daily · Apr 13

Crohn's vs. Ulcerative Colitis: Understanding IBD Symptoms, Causes & Treatment

Discover what sets Crohn's disease apart from ulcerative colitis. Explore IBD symptoms, how doctors diagnose these conditions, and effective treatment strategies.

Medical Daily · Jan 26

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

AnaptysBio Inc. (NASDAQ:ANAB) on Monday released data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis.

Benzinga · Nov 10, 2025

FDA Expands Johnson & Johnson Ulcerative Colitis Drug Approval To Pediatric Patients

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kg.

Benzinga · Oct 8, 2025

Long-Term Study Shows Sustained Remission With Eli Lilly's Ulcerative Colitis Drug

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment (up to four years total).

Benzinga · Oct 7, 2025

Told career was over, Dragon continues long road back

Cody Ramsey will cap a remarkable comeback from battling ulcerative colitis to captain St George Illawarra in the NSW Cup final.

AAP · Sep 24, 2025